Related to FDA Asks Spectrum Pharmaceuticals for Past Clinical Study Data to Help Expand Approval of NHL Drug

• FDA OKs Novartis' Drug for Childhood Arthritis
  
• Lilly Halts Development of Lymphoma Drug After Phase III Failure
  
• FDA Approves Roche EGFR Mutation CDx for NSCLC
  
• Bayer Prostate Cancer Drug Gains FDA Approval
  
• FDA cGMP Complaints Draw Boehringer Ingelheim Promise of Action
  
• Biovest’s Stock Value Triples with Phase III Data on Lymphoma Vaccine
  
• European Commission Clears Wyeth Drug for Relapsed and Refractory Mantle Cell Lymphoma
  
• FDA Notifies Spectrum that Its sNDA Does Not Support Fusilev Approval in Colorectal Cancer
  
• TopoTarget Earns $30M Up Front in Deal with Spectrum for Late-Stage Anticancer Agent
  
• Cell Therapeutics' Pixuvri Continues to Show Benefits in Pivotal NHL Trial
  
• Cell Therapeutics Signs Manufacturing Deal for Pixantrone with NerPharMa
  
• Cell Therapeutics Formally Appeals FDA’s Nonapprovable Ruling for Pixantrone
  
• Japan Approves Merck & Co.’s Gardasil, Zolinza, and Cubicin
  
• Spectrum Garners $9.5M in New Financing Round
  
• Spectrum Garners $10M in New Financing Round
  
• Allos Wins Accelerated Approval of Folotyn in Relapsed or Refractory Peripheral T-cell Lymphoma
  
• FDA Sanctions Gloucester Pharmaceuticals’ Cutaneous T-Cell Lymphoma Therapy
  
• Cell Therapeutics to Appeal FDA Decision on Pixantrone NDA
  
• Cell Therapeutics’ NHL Therapy Gets a Not Approvable Vote from FDA Committee
  
• FDA Requires More Clinical Work to Give Cell Therapeutics’ NHL Drug the Go-Ahead